The legal action centers on a period between April 16, 2025, and May 4, 2026, during which GeneDx executives allegedly touted the Fabric Genomics merger as a catalyst for efficiency. This narrative disintegrated on May 5, 2026, when the company revealed a $31.2 million impairment charge tied to the unit—roughly 94% of the original purchase price. The disclosure accompanied a Q1 earnings report that showed a tenfold increase in net losses and a sharp reduction in 2026 revenue guidance.

Beyond the impairment charges, the company faced a surprise shift in product mix toward lower-margin genome offerings, causing annual recurring revenue to miss internal targets. Reed Kathrein, the Hagens Berman partner overseeing the case, is now scrutinizing whether executives were aware of a stark disconnect between their public projections and the internal reality of their operations. The firm has set an August 3, 2026, deadline for investors to step forward as lead plaintiffs.

Following the market collapse, GeneDx appointed Mark Gardner as its new president, a move investigators are evaluating for potential links to the preceding governance failures. The firm is also soliciting information from whistleblowers who may hold non-public details regarding the company’s internal disclosures during the class period.